new anti-viral agent for chronic hepatitis B (CHB) in healthy adult subjects, CHB patients, 2

[1]  R. Colonno,et al.  Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance , 2008 .

[2]  M. Tolstrup,et al.  Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[4]  K. Steffy,et al.  [415] THE ACTIVE METABOLITE OF LB80380/ANA380, A NOVEL NUCLEOTIDE ANALOG, EXHIBITS ACTIVITY IN VITRO AGAINST MULTIPLE CLINICALLY RELEVANT HEPATITIS B VIRUS MUTANTS , 2007 .

[5]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[6]  A. Bisceglie,et al.  Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .

[7]  M. Yuen,et al.  Interim report for a phase II, multi-centre, dose-escalating study of LB80380/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV , 2005 .

[8]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[9]  K. Gough,et al.  Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .